We use cookies for a better user experience. Read our Privacy Policy

I Agree

Stroke Treatment Market

Stroke Treatment Market (Type: Ischemic Stroke and Hemorrhagic Stroke; Drug Class: Tissue Plasminogen Activators (tPA), Anticoagulants, Antiplatelets, Anticonvulsants, Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Oral Anticoagulants Help Minimize Risks of Internal Bleeding in Stroke Patients

Healthcare providers are recommending the consumption of non-vitamin K oral anticoagulants over commercially available medications such as Warfarin to reduce the incidence of atrial fibrillation in the stroke treatment market space. These efficacious oral anticoagulants are increasingly catching the attention of consumers and healthcare providers, as they effectively minimize the formation of clots in the blood. This is validated, as the revenue of anticoagulants amongst all drugs in the stroke treatment market is projected to hold the second-highest position, with a value of ~US$ 4.2 billion by 2027.

Oral anticoagulants are serving the convenience of stroke patients, as they can regularize any potential symptoms in home care settings. Thus, new oral anticoagulants are creating incremental opportunities for hospital, retail, and online pharmacies, as users can request for bulk orders at any given time. Healthcare companies in the stroke treatment market are developing improved formulations that make anticoagulants safer and help in reducing the risk of internal bleeding.

stroke treatment market infographic

To know the scope of our report Get a Sample on Stroke Treatment Market

Lucrative Opportunities in U.S. Catalyze Market Growth

Healthcare companies in the stroke treatment market should increase their focus on drug development in the U.S. Favorable guidelines by health commissions and the well-established healthcare infrastructure of the U.S. are gaining the worldwide attention of stakeholders in the stroke treatment market.

Overall, North America is anticipated to maintain its lead in terms of market share and revenue during the forecast period, with a projected value of ~US$ 6.9 billion by 2027, in the stroke treatment market. Developments in the North American healthcare landscape are creating a ripple effect in the stroke treatment landscape of the U.S.

The introduction of new guidelines by health commissions in the U.S. involves speeding up the procedure of providing thrombolytic therapy to patients suffering from acute ischemic stroke. These guidelines are increasing the convenience of patients, and healthcare providers are gaining credibility in the global stroke treatment market scenario. Healthcare providers in the U.S are aiming to increase speed targets every year. Also, patients are being provided intravenous tissue plasminogen activator (tPA) drugs within minutes of their hospital arrival.

Get a glimpse of the in-depth analysis through our Report Brochure

tPA Drugs Reduce Ischemia Injuries and Improve Neuroplasticity

Tissue plasminogen activator (tPA) drugs accounted for the highest revenue in 2018, with a global value of ~US$ 3.4 billion in the stroke treatment market. Healthcare companies gain monopoly through the sales of tPA drugs, as these are the only therapeutic agents meant to treat patients with acute ischemic stroke that have been approved by health commissions across nations. However, delayed administration of tPA drugs in acute ischemic stroke patients can lead to health complications such as intracranial hemorrhage (ICH), hemorrhagic transformation (HT), and mortality. To overcome this challenge, companies are educating healthcare professionals regarding the administration of tPA drugs within 4.5 hours of a stroke onset. Also, manufacturers are developing new drug agents with improved formulations that help reduce the incidence of ischemia injuries in case of delayed tPA administration.

As such, healthcare companies in the stroke treatment market are increasing the availability of recombinant tissue plasminogen activators (rt-PA) to ease the health complications of acute ischemic stroke patients with their thrombolytic action. Positive clinical trials have compelled healthcare providers to prescribe rt-PA drugs in order to improve neuroplasticity in stroke patients.

stroke treatment market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Manufacturers in the stroke treatment market are introducing reversal drug agents that minimize the incidence of life-threatening or uncontrolled bleeding in patients. Healthcare providers recommend the consumption of reversal agents in case oral anticoagulants are insufficient to treat stroke patients. Healthcare providers should increase their focus on non-pharmacological options such as percutaneous left atrial appendage occlusion for patients suffering from atrial fibrillation.

Though the market is expected to grow at a healthy CAGR of ~7%, manufacturers are challenged by the limitation of tPA drugs during delayed administration in patients. Hence, they should develop improved formulations of tPA that are efficacious, even after late administration of the drugs.

To contribute towards improving the quality of life in patients, companies should educate healthcare professionals to encourage patients for keeping a tab on weight management, as obesity leads to health complications such as sleep apnea, hypertension, hyperlipidemia, glucose intolerance, and the like.

Global Stroke Treatment Market: Overview

  • The global stroke treatment market was valued at ~US$ 8 Bn in 2018.
  • Projected to grow at a CAGR of ~7% over the forecast period, the global stroke treatment market is expected to reach a value of ~US$ 15 Bn by the year 2027.
  • Rise in the prevalence of stroke across the world, surge in the elderly patient pool, and rapid rise in comorbidities such as atrial fibrillation, diabetes, and hypertension leading to high risk of developing stroke are anticipated to drive the global stroke treatment market during the forecast period.
  • North America is the leading regional market in the global stroke treatment market, and will continue to have a major share throughout the forecast period of 2019 to 2027.
  • The stroke treatment market in Asia Pacific is expected to expand at a high CAGR of ~8% during the forecast period.

Global Stroke Treatment Market: Key Segments

  • In terms of type, the global stroke treatment market has been classified into ischemic stroke and hemorrhagic stroke. The ischemic stroke segment held a major share of the market in 2018, and the trend is anticipated to continue during the forecast period.
  • Based on drug class, the global market has been segmented into tissue plasminogen activators (tPA), anticoagulants, antiplatelets, anticonvulsants, and others. The tissue plasminogen activators (tPA) segment accounted for a majority of the market share in 2018.
  • In terms of distribution channel, the global stroke treatment market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held a major share of the global market in 2018, and this trend is expected to continue of the period of forecast.
  • The market value and forecasts for each of these segments have been provided from 2017 to 2027. The CAGRs of respective segments have also been provided from 2019 to 2027, considering 2018 as the base year.

Global Stroke Treatment Market: Regional Outlook

  • In terms of region, the global stroke treatment market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is projected to account for a leading share of the global market during the forecast period, owing to increase in the number of patients suffering from stroke.
  • For instance, according to the American Stroke Foundation, around 795,000 people experience a new or recurrent stroke each year in the U.S., which is anticipated to boost the stroke treatment market.
  • Favorable funding by governments and charitable trusts for stroke research, prevention, and treatment in the country is likely to drive the market in North America.
  • The stroke treatment market in Asia Pacific is projected to grow at a rapid pace in the next few years. India and China are anticipated to be lucrative markets for stroke treatment during the forecast period, owing to the high prevalence of cerebrovascular diseases, unhealthy lifestyle choices such as smoking, poor diets, and high incidence of diabetes and hypertension, which fuel the risk of developing a stroke.

Strategic Collaborations and Innovative Product Launches to Strengthen Market Position

  • In August 2017, Sanofi received FDA approval for PLAVIX (clopidogrel bisulfate), an antiplatelet medication used to reduce the risk of heart disease and stroke.
  • In December 2017, Bristol-Myers Squibb Company and Pfizer Alliance, along with the National Stroke Association and iHeartMedia, launched ‘Tune in to AFib, Take Note of Stroke Risk’. This initiative aims to educate and create awareness among people living with atrial fibrillation (AFib) about the increased risk of stroke.
  • In April 2016, Bristol-Myers Squibb Company entered into a collaboration with Janssen Pharmaceuticals, Inc. to develop and commercialize BMS-986177, a Factor XIa (FXIa) inhibitor. It is an anticoagulant drug indicated for the prevention and treatment of thrombotic events.

Emerging Economies to be Highly Lucrative Markets for Stroke Treatment

  • Emerging economies such as India and China offer significant opportunities in the stroke treatment market.
  • Rise in the prevalence and incidence of stroke in developing countries such as India and China, affecting large the elderly patient pool, offers significant opportunity to market players to exploit these untapped regions.
  • Patients suffering from atrial fibrillation are at high risk of developing stroke. All these factors will provide significant opportunities to regional players in the market in the near future.

Global Stroke Treatment Market: Key Companies

  • Key players in the global stroke treatment market have been profiled based on attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies
  • Major companies profiled in the global market report are
    • Bristol-Myers Squibb Company,
    • Sanofi,
    • Johnson & Johnson Services, Inc.
    • Boehringer Ingelheim GmbH
    • F. Hoffmann-La Roche (Genentech)
    • Daiichi Sankyo Company, Limited 
    • Amgen Inc., AstraZeneca
    • Biogen Inc.

Global Stroke Treatment Market – Segmentation

Type

Ischemic Stroke

Hemorrhagic Stroke

Drug Class

Tissue Plasminogen Activators (tPA)

Anticoagulants

Antiplatelets

Anticonvulsants

Others

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Stroke Treatment Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of stroke treatment market?

Stroke treatment market to reach a value of ~US$ 4.2 billion by 2027

What is the anticipated CAGR of the stroke treatment market in the forecast period?

Stroke treatment market is projected to grow at a CAGR of ~7% during 2019 - 2027

What are the key driving factors for the growth of the stroke treatment market?

Stroke treatment market is driven by rise in the prevalence of stroke across the world

Which region is expected to project the highest market share in the global stroke treatment market?

North America accounted for a major share of the global stroke treatment market

Who are the key players in the stroke treatment market?

Key players in the global stroke treatment market include Bristol-Myers Squibb Company, Sanofi, Johnson & Johnson Services, Inc., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche (Genentech)

1. Preface 

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Stroke Treatment Market

4. Market Overview

    4.1. Introduction

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Stroke Treatment Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

    5.1. Key Industry Developments 

    5.2. Pipeline Analysis

    5.3. Epidemiology Analysis

6. Global Stroke Treatment Market Value and Forecast, by Type 

    6.1. Introduction & Definition 

    6.2. Global Stroke Treatment Market Value Forecast, by Type, 2017–2027

        6.2.1. Ischemic Stroke

        6.2.2. Hemorrhagic Stroke

    6.3. Global Stroke Treatment Market Attractiveness, by Type

7. Global Stroke Treatment Market Value and Forecast, by Drug Class 

    7.1. Introduction & Definition 

    7.2. Global Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027

        7.2.1. Tissue Plasminogen Activator (tPA)

        7.2.2. Anticoagulants

        7.2.3. Antiplatelets

        7.2.4. Anticonvulsants

        7.2.5. Others

    7.3. Global Stroke Treatment Market Attractiveness, by Drug Class

8. Global Stroke Treatment Market Value and Forecast, by Distribution Channel

    8.1. Introduction 

    8.2. Global Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027

        8.2.1. Hospital Pharmacies

        8.2.2. Retail Pharmacies

        8.2.3. Online Pharmacies

    8.3. Global Stroke Treatment Market Attractiveness, by Distribution Channel

9. Global Stroke Treatment Market Value and Forecast, by Region

    9.1. Introduction 

    9.2. Stroke Treatment Market Value Forecast, by Region, 2017–2027

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Global Stroke treatment Market Attractiveness, by Region

10. North America Stroke Treatment Market Analysis and Forecast 

    10.1. Introduction

    10.2. North America Stroke Treatment Market Value Forecast, by Type, 2017–2027

        10.2.1. Ischemic Stroke 

        10.2.2. Hemorrhagic Stroke 

    10.3. North America Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027

        10.3.1. Tissue Plasminogen Activator (tPA)

        10.3.2. Anticoagulants

        10.3.3. Antiplatelets

        10.3.4. Anticonvulsants

        10.3.5. Others

    10.4. North America Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. North America Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Stroke treatment Market Attractiveness Analysis

        10.6.1. By Type

        10.6.2. By Drug Class

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe Stroke Treatment Market Analysis and Forecast 

    11.1. Introduction

    11.2. Europe Stroke Treatment Market Value Forecast, by Type, 2017–2027

        11.2.1. Ischemic Stroke 

        11.2.2. Hemorrhagic Stroke 

    11.3. Europe Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027

        11.3.1. Tissue Plasminogen Activator (tPA)

        11.3.2. Anticoagulants

        11.3.3. Antiplatelets

        11.3.4. Anticonvulsants

        11.3.5. Others

    11.4. Europe Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Europe Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy 

        11.5.6. Rest of Europe

    11.6. Europe Stroke treatment Market Attractiveness Analysis

        11.6.1. By Type

        11.6.2. By Drug Class

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific Stroke Treatment Market Analysis and Forecast 

    12.1. Introduction

    12.2. Asia Pacific Stroke Treatment Market Value Forecast, by Type, 2017–2027

        12.2.1. Ischemic Stroke 

        12.2.2. Hemorrhagic Stroke 

    12.3. Asia Pacific Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027

        12.3.1. Tissue Plasminogen Activator (tPA)

        12.3.2. Anticoagulants

        12.3.3. Antiplatelets

        12.3.4. Anticonvulsants

        12.3.5. Others

    12.4. Asia Pacific Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Asia Pacific Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

        12.5.1. Japan

        12.5.2. China

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific Stroke treatment Market Attractiveness Analysis

        12.6.1. By Type

        12.6.2. By Drug Class

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region 

13. Latin America Stroke Treatment Market Analysis and Forecast 

    13.1. Introduction

    13.2. Latin America Stroke Treatment Market Value Forecast, by Type, 2017–2027

        13.2.1. Ischemic Stroke 

        13.2.2. Hemorrhagic Stroke 

    13.3. Latin America Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027

        13.3.1. Tissue Plasminogen Activator (tPA)

        13.3.2. Anticoagulants

        13.3.3. Antiplatelets

        13.3.4. Anticonvulsants

        13.3.5. Others

    13.4. Latin America Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Latin America Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Latin America Stroke treatment Market Attractiveness Analysis

        13.6.1. By Type

        13.6.2. By Drug Class

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa Stroke treatment Market Analysis and Forecast 

    14.1.  Introduction

    14.2. Middle East & Africa Stroke Treatment Market Value Forecast, by Type, 2017–2027

        14.2.1. Ischemic Stroke 

        14.2.2. Hemorrhagic Stroke 

    14.3. Middle East & Africa Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027

        14.3.1. Tissue Plasminogen Activator (tPA)

        14.3.2. Anticoagulants

        14.3.3. Antiplatelets

        14.3.4. Anticonvulsants

        14.3.5. Others

    14.4. Middle East & Africa Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Middle East & Africa Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Middle East & Africa Stroke treatment Market Attractiveness Analysis

        14.6.1. By Type

        14.6.2. By Drug Class

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1.  Global Stroke Treatment Market Position Analysis, by Company, 2018

    15.2.  Company Profiles

        15.2.1. Bristol-Myers Squibb Company

            15.2.1.1. Company Description

            15.2.1.2. Business Overview

            15.2.1.3. Financial Overview

            15.2.1.4. Strategic Overview

            15.2.1.5. SWOT Analysis

        15.2.2. Boehringer Ingelheim GmbH

            15.2.2.1. Company Description

            15.2.2.2. Business Overview

            15.2.2.3. Financial Overview

            15.2.2.4. Strategic Overview

            15.2.2.5. SWOT Analysis

        15.2.3. Daiichi Sankyo Company, Limited 

            15.2.3.1. Company Description

            15.2.3.2. Business Overview

            15.2.3.3. Financial Overview

            15.2.3.4. Strategic Overview

            15.2.3.5. SWOT Analysis

        15.2.4. F. Hoffmann-La Roche Ltd 

            15.2.4.1. Company Description

            15.2.4.2. Business Overview

            15.2.4.3. Financial Overview

            15.2.4.4. Strategic Overview

            15.2.4.5. SWOT Analysis

        15.2.5. Johnson & Johnson Services, Inc.

            15.2.5.1. Company Description

            15.2.5.2. Business Overview

            15.2.5.3. Financial Overview

            15.2.5.4. Strategic Overview

            15.2.5.5. SWOT Analysis

        15.2.6. Sanofi

            15.2.6.1. Company Description

            15.2.6.2. Business Overview

            15.2.6.3. Financial Overview

            15.2.6.4. Strategic Overview

            15.2.6.5. SWOT Analysis

        15.2.7. Amgen, Inc.

            15.2.7.1. Company Description

            15.2.7.2. Business Overview

            15.2.7.3. Financial Overview

            15.2.7.4. Strategic Overview

            15.2.7.5. SWOT Analysis

        15.2.8. Biogen Inc.

            15.2.8.1. Company Description

            15.2.8.2. Business Overview

            15.2.8.3. Financial Overview

            15.2.8.4. Strategic Overview

            15.2.8.5. SWOT Analysis

        15.2.9. AstraZeneca 

            15.2.9.1. Company Description

            15.2.9.2. Business Overview

            15.2.9.3. Financial Overview

            15.2.9.4. Strategic Overview

            15.2.9.5. SWOT Analysis

List of Tables

Table 01: Pipeline Analysis for Stroke Treatment

Table 02: Global Stroke Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

Table 03: Global Stroke Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 04: Global Stroke Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 05: Global Stroke Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 06: North America Stroke Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 07: North America Stroke Treatment Market Value (US$ Mn) Forecast, by Type, 2017?2027

Table 08: North America Stroke Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 09: North America Stroke Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017?2027

Table 10: Europe Stroke Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 11: Europe Stroke Treatment Market Value (US$ Mn) Forecast, by Type, 2017?2027

Table 12: Europe Stroke Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 13: Europe Stroke Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017?2027

Table 14: Asia Pacific Stroke Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 15: Asia Pacific Stroke Treatment Market Value (US$ Mn) Forecast, by Type, 2017?2027

Table 16: Asia Pacific Stroke Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 17: Asia Pacific Stroke Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017?2027

Table 18: Latin America Stroke Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 19: Latin America Stroke Treatment Market Value (US$ Mn) Forecast, by Type, 2017?2027

Table 20: Latin America Stroke Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 21: Latin America Stroke Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017?2027

Table 22: Middle East & Africa Stroke Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 23: Middle East & Africa Stroke Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017?2027

Table 24: Middle East & Africa Stroke Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 25: Middle East & Africa Stroke Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017?2027

List of Figures

Figure 01: Global Stroke Treatment Market Value (US$ Mn) and Distribution (%), by Region, 2019 and 2027

Figure 02: Global Stroke Treatment Market Value (US$ Mn) Forecast, 2017–2027

Figure 03: Global Stroke Treatment Market Value Share (%), by Type, 2018

Figure 04: Global Stroke Treatment Market Value Share (%), by Drug Class, 2018

Figure 05: Global Stroke Treatment Market Value Share (%), by Distribution Channel, 2018

Figure 06: Global Stroke Treatment Market Value Share (%), by Region, 2018

Figure 07: Stroke Treatment Market - Agreements, Collaborations, Partnerships & New Product Launch 

Figure 08: Epidemiology of Stroke

Figure 09: Global Stroke Treatment Market Value Share (%), by Type, 2018 and 2027

Figure 10: Global Stroke Treatment Market Attractiveness, by Type, 2019–2027

Figure 11: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Ischemic Stroke, 2017–2027

Figure 12: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hemorrhagic Stroke, 2017–2027

Figure 13: Global Stroke Treatment Market Value Share (%), by Drug Class, 2018 and 2027

Figure 14: Global Stroke Treatment Market Attractiveness, by Drug Class, 2019–2027

Figure 15: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Tissue Plasminogen Activator (tPA), 2017–2027

Figure 16: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anticoagulants, 2017–2027

Figure 17: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antiplatelets, 2017–2027

Figure 18: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anticonvulsants, 2017–2027

Figure 19: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 20: Global Stroke Treatment Market Value Share (%), by Distribution Channel, 2018 and 2027

Figure 21: Global Stroke Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 22: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027

Figure 23: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027

Figure 24: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027

Figure 25: Global Stroke Treatment Market Value Share Analysis, by Region, 2018 and 2027

Figure 26: Global Stroke Treatment Market Attractiveness Analysis, by Region, 2019–2027

Figure 27: North America Stroke Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 28: North America Stroke Treatment Market Value Share Analysis, by Country, 2018 and 2027

Figure 29: North America Stroke Treatment Market Attractiveness Analysis, by Country, 2019–2027

Figure 30: North America Stroke Treatment Market Value Share (%), by Type, 2018 and 2027

Figure 31: North America Stroke Treatment Market Attractiveness, by Type, 2019–2027

Figure 32: North America Stroke Treatment Market Value Share (%), by Drug Class, 2018 and 2027

Figure 33: North America Stroke Treatment Market Attractiveness, by Drug Class, 2019–2027

Figure 34: North America Stroke Treatment Market Value Share (%), by Distribution Channel, 2018 and 2027

Figure 35: North America Stroke Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 36: Europe Stroke Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 37: Europe Stroke Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 38: Europe Stroke Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 39: Europe Stroke Treatment Market Value Share (%), by Type, 2018 and 2027

Figure 40: Europe Stroke Treatment Market Attractiveness, by Type, 2019–2027

Figure 41: Europe Stroke Treatment Market Value Share (%), by Drug Class, 2018 and 2027

Figure 42: Europe Stroke Treatment Market Attractiveness, by Drug Class, 2019–2027

Figure 43: Europe Stroke Treatment Market Value Share (%), by Distribution Channel, 2018 and 2027

Figure 44: Europe Stroke Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 45: Asia Pacific Stroke Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 46: Asia Pacific Stroke Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 47: Asia Pacific Stroke Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 48: Asia Pacific Stroke Treatment Market Value Share (%), by Type, 2018 and 2027

Figure 49: Asia Pacific Stroke Treatment Market Attractiveness, by Type, 2019–2027

Figure 50: Asia Pacific Stroke Treatment Market Value Share (%), by Drug Class, 2018 and 2027

Figure 51: Asia Pacific Stroke Treatment Market Attractiveness, by Drug Class, 2019–2027

Figure 52: Asia Pacific Stroke Treatment Market Value Share (%), by Distribution Channel, 2018 and 2027

Figure 53: Asia Pacific Stroke Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 54: Latin America Stroke Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 55: Latin America Stroke Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 56: Latin America Stroke Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 57: Latin America Stroke Treatment Market Value Share (%), by Type, 2018 and 2027

Figure 58: Latin America Stroke Treatment Market Attractiveness, by Type, 2019–2027

Figure 59: Latin America Stroke Treatment Market Value Share (%), by Drug Class, 2018 and 2027

Figure 60: Latin America Stroke Treatment Market Attractiveness, by Drug Class, 2019–2027

Figure 61: Latin America Stroke Treatment Market Value Share (%), by Distribution Channel, 2018 and 2027

Figure 62: Latin America Stroke Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 63: Middle East & Africa Stroke Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 64: Middle East & Africa Stroke Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 65: Middle East & Africa Stroke Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 66: Middle East & Africa Stroke Treatment Market Value Share (%), by Type, 2018 and 2027

Figure 67: Middle East & Africa Stroke Treatment Market Attractiveness, by Type, 2019–2027

Figure 68: Middle East & Africa Stroke Treatment Market Value Share (%), by Drug Class, 2018 and 2027

Figure 69: Middle East & Africa Stroke Treatment Market Attractiveness, by Drug Class 2019–2027

Figure 70: Middle East & Africa Stroke Treatment Market Value Share (%), by Distribution Channel, 2018 and 2027

Figure 71: Middle East & Africa Stroke Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 72: Global Stroke Treatment Market Position Analysis, by Top Company Ranking, 2018

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

211

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved